BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30101858)

  • 1. Phenotypic Screening Using Patient-Derived Induced Pluripotent Stem Cells Identified Pyr3 as a Candidate Compound for the Treatment of Infantile Hypertrophic Cardiomyopathy.
    Sakai T; Naito AT; Kuramoto Y; Ito M; Okada K; Higo T; Nakagawa A; Shibamoto M; Yamaguchi T; Sumida T; Nomura S; Umezawa A; Miyagawa S; Sawa Y; Morita H; Lee JK; Shiojima I; Sakata Y; Komuro I
    Int Heart J; 2018 Sep; 59(5):1096-1105. PubMed ID: 30101858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
    Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
    J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations.
    Zhou W; Bos JM; Ye D; Tester DJ; Hrstka S; Maleszewski JJ; Ommen SR; Nishimura RA; Schaff HV; Kim CS; Ackerman MJ
    J Cardiovasc Transl Res; 2019 Oct; 12(5):394-403. PubMed ID: 30796699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
    Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
    Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
    Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
    Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying Patient-Specific Induced Pluripotent Stem Cells to Create a Model of Hypertrophic Cardiomyopathy.
    Dementyeva EV; Medvedev SP; Kovalenko VR; Vyatkin YV; Kretov EI; Slotvitsky MM; Shtokalo DN; Pokushalov EA; Zakian SM
    Biochemistry (Mosc); 2019 Mar; 84(3):291-298. PubMed ID: 31221067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
    Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
    Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling hypertrophic cardiomyopathy with human cardiomyocytes derived from induced pluripotent stem cells.
    Li J; Feng X; Wei X
    Stem Cell Res Ther; 2022 Jun; 13(1):232. PubMed ID: 35659761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation.
    Li S; Pan H; Tan C; Sun Y; Song Y; Zhang X; Yang W; Wang X; Li D; Dai Y; Ma Q; Xu C; Zhu X; Kang L; Fu Y; Xu X; Shu J; Zhou N; Han F; Qin D; Huang W; Liu Z; Yan Q
    Stem Cell Reports; 2018 Mar; 10(3):808-821. PubMed ID: 29456182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
    Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
    Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the cardiac pathology of SCO2-mediated hypertrophic cardiomyopathy using patients induced pluripotent stem cell-derived cardiomyocytes.
    Hallas T; Eisen B; Shemer Y; Ben Jehuda R; Mekies LN; Naor S; Schick R; Eliyahu S; Reiter I; Vlodavsky E; Katz YS; Õunap K; Lorber A; Rodenburg R; Mandel H; Gherghiceanu M; Binah O
    J Cell Mol Med; 2018 Feb; 22(2):913-925. PubMed ID: 29193756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for
    Kondo T; Higo S; Shiba M; Kohama Y; Kameda S; Tabata T; Inoue H; Okuno S; Ogawa S; Nakamura S; Takeda M; Ito E; Li J; Liu L; Kuramoto Y; Lee JK; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
    Circ Genom Precis Med; 2022 Oct; 15(5):e003522. PubMed ID: 35861968
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Higgins EM; Bos JM; Dotzler SM; John Kim CS; Ackerman MJ
    Circ Genom Precis Med; 2019 Nov; 12(11):e002648. PubMed ID: 31638832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent effects of adrenaline in human induced pluripotent stem cell-derived cardiomyocytes obtained from hypertrophic cardiomyopathy.
    Prajapati C; Ojala M; Aalto-Setälä K
    Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29361520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Streckfuss-Bömeke K; Tiburcy M; Fomin A; Luo X; Li W; Fischer C; Özcelik C; Perrot A; Sossalla S; Haas J; Vidal RO; Rebs S; Khadjeh S; Meder B; Bonn S; Linke WA; Zimmermann WH; Hasenfuss G; Guan K
    J Mol Cell Cardiol; 2017 Dec; 113():9-21. PubMed ID: 28941705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertrophic cardiomyopathy in Noonan syndrome.
    Nishikawa T; Ishiyama S; Shimojo T; Takeda K; Kasajima T; Momma K
    Acta Paediatr Jpn; 1996 Feb; 38(1):91-8. PubMed ID: 8992870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
    Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
    J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.
    Wijnker PJM; Dinani R; van der Laan NC; Algül S; Knollmann BC; Verkerk AO; Remme CA; Zuurbier CJ; Kuster DWD; van der Velden J
    Cardiovasc Res; 2024 Mar; 120(3):301-317. PubMed ID: 38240646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of cardiac metabolism in iPSC-derived cardiomyocytes: lessons from maturation and disease modeling.
    Vučković S; Dinani R; Nollet EE; Kuster DWD; Buikema JW; Houtkooper RH; Nabben M; van der Velden J; Goversen B
    Stem Cell Res Ther; 2022 Jul; 13(1):332. PubMed ID: 35870954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.